LivaNova to Present at the UBS Global Healthcare Conference

LONDON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24LIVN&src=ctag” target=”_blank”gt;$LIVNlt;/agt;–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company,
today announced Damien McDonald, Chief Executive Officer, and Thad
Huston, Chief Financial Officer, will present at the UBS Global
Healthcare Conference on Wednesday, May 22 in New York at 10 a.m.
Eastern Time.

The discussion will be available to all interested parties through a
live audiocast accessible via the Investor Relations section of the
LivaNova website at www.livanova.com.
Listeners should log on approximately 10 minutes in advance to ensure
proper setup to receive the audiocast. Replays of the webcast will be
available on the LivaNova website within 24 hours after the live
presentation for 90 days after the event.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova’s advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London, LivaNova has a presence in more than 100 countries worldwide.
The Company currently employs approximately 4,000 employees.
LivaNova operates as two businesses: Cardiovascular and Neuromodulation,
with operating headquarters in Mirandola (Italy) and Houston (U.S.),
respectively.

For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as amended,
and Section 21E of the United States Securities Exchange Act of 1934, as
amended. Forward-looking statements are not historical facts but are
based on certain assumptions of management and describe LivaNova’s
future plans, strategies and expectations. Forward-looking statements
can generally be identified by the use of forward-looking terminology,
including, but not limited to, “may,” “could,” “seek,” “guidance,”
“predict,” “potential,” “likely,” “believe,” “will,” “expect,”
“anticipate,” “estimate,” “plan,” “intend,” “forecast,” or variations of
these terms and similar expressions, or the negative of these terms or
similar expressions. Forward-looking statements contained in this news
release are based on information presently available to LivaNova and
assumptions that LivaNova believes to be reasonable, but are inherently
uncertain. As a result, LivaNova’s actual results, performance or
achievements may differ materially from those expressed or implied by
these forward-looking statements, which are not guarantees of future
performance or actions that may be taken by LivaNova and involve known
and unknown risks, uncertainties and other factors that are, in some
cases, beyond LivaNova’s control. You should carefully consider the
risks and uncertainties that affect LivaNova, including those described
in the “Risk Factors” section of LivaNova’s Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other
documents filed from time to time with the United States Securities and
Exchange Commission.

All information in this news release is as of the date of its release.
LivaNova does not undertake or assume any obligation to update publicly
any of the forward-looking statements in this news release to reflect
actual results, new information or future events, changes in assumptions
or changes in other factors affecting forward-looking statements, except
to the extent required by applicable law. If we update one or more
forward-looking statements, no inference should be drawn that we will
make additional updates with respect to those or other forward-looking
statements. We caution you not to place undue reliance on any
forward-looking statements, which are made only as of the date of this
news release.

Contacts

LivaNova PLC Investor Relations and Media
Melissa Farina, +1
(281) 228-7262
Vice President, Investor Relations
investorrelations@livanova.com

Deanna Wilke, +1 (281) 727-2764
Director, Corporate
Communications
corporate.communications@livanova.com